Proton Pump Inhibitors Do Not Counteract Benefits Of Antiplatelet Drugs Clopidogrel Or Prasugrel In Patients After An Acute Coronary Syndrome

Medical News Today -- An article published Online First and in a future edition of The Lancet reports that proton pump inhibitors (PPIs) do not interfere with the clinical benefit of the anticlotting drugs clopidogrel or prasugrel (thienopyridines) in patients after an acute coronary syndrome such as heart attack or unstable angina. PPIs are a commonly prescribed antacid medication. The article is the work of Dr Michelle O'Donoghue, Brigham and Women's Hospital, Boston, MA, USA, and colleagues. These findings are quite the opposite of the conclusions of other recent studies that have confirmed that there is potential harm when these two classes of drugs are combined.